Welcome to
Prosigna is 510(k) cleared and CE marked. Prosigna is available to healthcare professionals in the United States, in markets that recognize the CE mark, and/or in which Prosigna is registered.
I am a healthcare professional in the US
I am a healthcare professional outside the US

Now included 4 Clinical Practice Guidelines

Home
This site is intended for US residents only.
Prosigna is indicated for use in postmenopausal women with hormone receptor-positive, node-negative (Stage I or Stage II), or node-positive (Stage III) breast cancer to be treated with adjuvant endocrine therapy.
Prosigna Package Insert
Prosigna MSDS
Prosigna product data sheet

Prosigna Product Data Sheet

nCounter User Manual

nCounter®
User Manual

get_adobe_reader